Last reviewed · How we verify
recombinant human erythropoietin, rhEpo — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
recombinant human erythropoietin, rhEpo (recombinant human erythropoietin, rhEpo) — Claudia Sue Robertson.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| recombinant human erythropoietin, rhEpo TARGET | recombinant human erythropoietin, rhEpo | Claudia Sue Robertson | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- recombinant human erythropoietin, rhEpo CI watch — RSS
- recombinant human erythropoietin, rhEpo CI watch — Atom
- recombinant human erythropoietin, rhEpo CI watch — JSON
- recombinant human erythropoietin, rhEpo alone — RSS
Cite this brief
Drug Landscape (2026). recombinant human erythropoietin, rhEpo — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-human-erythropoietin-rhepo. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab